Billionaire Stanley Druckenmiller Sold Palantir And Bought This Stock Instead

Photo of Joey Frenette
By Joey Frenette Updated Published

Key Points

  • Teva’s turnaround plan is finally starting to pay off. The smart money is paying close attention.

  • Teva stock remains dirt-cheap with a low single-digit P/E multiple and plenty of underrated, growthy products in the branded portfolio.

  • It sounds nuts, but SoFi is giving new active invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for yourself (Sponsor)
    DISCLOSURE:
    INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Billionaire Stanley Druckenmiller Sold Palantir And Bought This Stock Instead

© Neilson Barnard / Getty Images Entertainment via Getty Images

Billionaire investment legend Stanley Druckenmiller is quickly becoming one of my favorite big-money managers to follow quarter to quarter. He’s not just limiting himself to value stocks, but has shown a knack for spotting opportunities within the high-tech, hyper-growth corners of the stock market, as demonstrated by his previous buy of Palantir (NASDAQ:PLTR | PLTR Price Prediction) stock, which he’s now completely sold out of.

That said, with CEO Alex Karp selling shares, I think it’s only wise to take big profits where there are big profits to be had. And with shares of the big data AI firm pulling back close to 10% last week as the S&P 500 blasted off to hit a new all-time high, the overheated, overbought name certainly looks to be getting a bit toppy. Either way, Druckenmiller has booked profits and has been busy putting it to work in other opportunities in the first quarter. 

Druckenmiller scoops up dirt-cheap shares of Teva Pharmaceuticals in the first quarter

The most notable move from Druckenmiller in Q1 has to be the boosting of his stake in Israeli drugmaker Teva Pharmaceuticals (NYSE:TEVA), which is now his fund’s second-largest holding with a 7.7% weighting. For the first quarter, Druckenmiller’s fund hiked its position by more than 65% (which works out to around 5.9 million shares).

Undoubtedly, Teva stands in stark contrast to Palantir, one of the most explosive momentum stocks in the tech sector. While shares of Teva have enjoyed some nice newfound momentum in the past two years, now up 123% in the timespan, the longer-term picture doesn’t look nearly as pretty.

Around a decade ago, the stock fell off a cliff, shedding close to 90% of its value from peak to trough. After spending a few years fluctuating wildly in the single digits and low teens, the name may have been viewed as dead money by most, but a deep-value play by other, more patient investors. With newfound momentum to get behind and a huge vote of confidence from Druckenmiller, Teva now seems worthy of a second look for investors who may have forgotten about it since its catastrophic implosion.

So, is the long-time laggard finally ready to come back to life? Or is the latest two-year rally going to pave the way for another painful pullback?

Teva’s new products are enjoying impressive growth

Teva’s recent quarters unveiled strength in a number of its branded drugs, which are now growing at an impressive double-digit pace. Indeed, the company’s “Pivot to Growth” efforts are showing early signs of paying off. With impressive margin gains and respectable growth from its innovative medicines to help the firm save around $700 million by 2027, the stage certainly seems set for continued gains. 

Recently, Goldman Sachs (NYSE:GS) analyst Matt Dellatorre praised Teva as a buy, citing improvement in the firm’s core business and strong growth to be had from the branded portfolio. With a $24.00 price target, which is $6.00 shy of the current Wall Street high, Teva could be looking at a 44% gain from Friday’s closing price if all goes well over the next year or so. In any case, I think Druckenmiller will be proven right again, as Teva continues putting up the solid quarters while convincing a number of Wall Street analysts to change their tune on a name that’s been dragging its feet for far too long.

The bottom line: Teva stock looks dirt-cheap, with plenty of support behind its impressive rally

With a 6.37 times forward price-to-earnings (P/E) multiple, perhaps it’s no mystery as to why so many Wall Street pros and a legend in Druckenmiller are bullish on the name. Teva’s growth pivot is well underway, and its stock may very well be subject to further multiple expansion as the fallen pharma firm looks to make up for lost time in the second half.

Photo of Joey Frenette
About the Author Joey Frenette →

Joey is a 24/7 Wall St. contributor and seasoned investment writer whose work can also be found in publications such as The Motley Fool and TipRanks. Holding a B.A.Sc in Computer Engineering from the University of British Columbia (UBC), Joey has leveraged his technical background to provide insightful stock analyses to readers.

Joey's investment philosophy is heavily influenced by Warren Buffett's value investing principles. As a dedicated Buffett disciple, Joey is committed to unearthing value in the tech sector and beyond.

Continue Reading

Top Gaining Stocks

ENPH Vol: 20,331,230
DXCM Vol: 11,133,392
FDS Vol: 1,192,775
WDAY Vol: 5,160,389
NOW Vol: 34,569,747

Top Losing Stocks

CTRA Vol: 73,319,495
GLW Vol: 17,221,470
COIN Vol: 14,429,129
F Vol: 108,272,348
MU Vol: 48,532,352